A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry Disease

NCT00140621 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

6

Enrollment

INDUSTRY

Sponsor class

Conditions

Fabry Disease

Interventions

DRUG: Agalsidase beta

Sponsor

Genzyme, a Sanofi Company